Abstract
Conclusions:
This study showed that PDT could stabilize visual acuity in patients with PCV.
Results:
Five eyes of 5 patients with polypoidal choroidal vasculopathy were enrolled. Follow up ranged from 12 to 30 months. Baseline mean visual acuity was 0,62±0,2 logMAR, 0,46±0,2 by 1and 3 months, 0,42±0,3 by 6 months, 0,42±0,3 by 12 months. At the end of 1 year, there was no change in visual acuity in 2 (40%) patients, and 1 or 6 lines increase in 3 (60%) patients, there was no visual acuity decrease regarding to baseline measurements.
Methods:
Visual acuity testing, ophthalmological examination, color photographs, fluorescein and indocyanine green angiographies were used to evaluate the results of PDT. Follow up examination were scheduled at 1 and 3 months after the treatment and then 3 months apart. Retreatments were considered when leakage was observed at 3 months after the treatment and thereafter.
Purpose:
The aim of this study is to evaluate the results of photodynamic therapy (PDT) in patients with polypoidal choroidal vasculopathy (PCV).
Keywords: polypoidal choroidal vasculopathy, photodynamic therapy
References
Treatment of age related macular degeneration with photodynamic therapy (TAP) Study Group, Photodynamic therapy of subfoveal choroidal neovascularization in agerelated macular degeneration with verteporfin. One-year results of 2 randomized clinical trials- TAP report 1. Arch Ophthalmol 1999,117-1329
Yannuzzi LA, Sorenson J, Spaide RF, et al, Idiopathic polypoidal choriodal vasculopaty (IPCV). Retina 1990,10-1
Stern RM, Zakov N, Zegarra H, et al, Multiple recurrent sero-sanguineous retinal pigment epithelial detachments in black women. Am J Ophthalmol 1985,100-560
Kleiner RC, Brucker AJ, Johnston RL, et al, The posterior uveal bleeding syndrome. Retina 1990,10-9
Yannuzzi LA, Wong DWK, Storzolini BS, et al, Polipoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol 1999,117-1503
MacCumber MV, Dastgheib K, Bressler NM, et al, Clinicopathologic correlation of the multiple recurrent serosanguineous retinal pigment epithelial detachments syndrome. Retina 1994,14-143
Uyama M, Matsubara T, Fukushima I, et al, Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol 1999,117-1035
Spaide R, Donsoff I, Deborah BA, et al, Treatment of polipoidal choroidal vasculopathy with photodynamic therapy. Retina 2002,22-529
Eandi CM, Ober M, Freund B, et al, Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. Retina 2007,27-825
Lee MW, Yeo I, Wong D, et al, Photodynamic therapy with verteporfin for polipoidal choroidal vasculopathy. Eye 2008,265-1
Yannuzzi LA, Chiardella A, Spaide R, et al, The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 1997,115-478
Wong DWK, Spaide RF, Goldbaum M, et al, Idiopathic polypoidal choroidal vasculopathy in a patient with angioid streaks. Retina. 2001,21-121
Uyama M, Wada M, Naga Y, et al, Polipoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002,133-639
Gomez-Ulla F, Gonzales F, Torreiro MG, Diode laser photocoagulation in idiopathic polypoidal choroidal vasculopathy.  Retina 1998,18-481
Astam N, zmert E, Batioglu F, Yasa bagli makula dejeneresansli retinal anjiomatöz proliferasyon ve polipoidal koroidal vaskülopati olgularinda fotodinamik/kombine tedavi sonuçlari. Retina &ndash Vitreus 2007,15-81
Akaza E, Yuzava M, Matsumoto Y, et al, Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2007,51-270
